Key result
Cardiac gene therapy with angiogenic factors shows safety and efficacy in experimental and clinical studies for diffuse coronary artery disease, though it has not yet achieved commercial approval.
Cardiac gene therapy using angiogenic factors represents a promising therapeutic approach for diffuse coronary artery disease, though further refinement in product design and evaluation is needed for commercial approval.
Should not change practice for diffuse CAD; leaves open need for refined designs and larger trials.
Cardiac gene therapy offers a strategy to treat diffuse coronary artery disease (CAD), a disorder with no therapeutic options. The use of genes to revascularize the ischemic myocardium has been the focus of two decades of preclinical research with a variety of angiogenic mediators, including vascular endothelial growth factor, fibroblast growth factor, hepatocyte growth factor, and others encoded by DNA plasmids or adenovirus vectors. The multifaceted challenge for developing efficient induction of collateral vessels in the ischemic heart requires a choice for route of delivery, dosing level, a relevant animal model, duration of treatment, and assessment of phenotype for efficacy. Overall, studies of gene therapy for ischemia in experimental models are very encouraging, with clear evidence of safety and efficacy, strongly supporting the concept that gene therapy to induce angiogenesis is a viable therapeutic approach for CAD. Clinical studies of cardiac gene therapy with angiogenic factors have added substantially to the evidence for efficacy, but definitive studies have not yet led to commercial approval. This review provides the general concepts for angiogenesis-based therapeutic approaches for diffuse CAD and summarizes the results from key studies in the field with recommendations for refinement to a successful product design and evaluation.
No takes yet. Share an insight, caveat, or question.
Kaminsky et al. (2013) conducted a review in Diffuse coronary artery disease (CAD). Cardiac gene therapy with angiogenic factors was evaluated. Cardiac gene therapy with angiogenic factors shows safety and efficacy in experimental and clinical studies for diffuse coronary artery disease, though it has not yet achieved commercial approval.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: